New hope for advanced lung cancer: experimental combo therapy enters phase 2 trial
NCT ID NCT07175220
First seen Nov 01, 2025 · Last updated May 09, 2026 · Updated 34 times
Summary
This study tests a new drug, SHR2554, combined with other cancer treatments for people with advanced non-small cell lung cancer that cannot be removed by surgery or has spread. The goal is to see if the combination is safe and shrinks tumors. About 200 adults aged 18-75 with good organ function and performance status are eligible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
Contact
Conditions
Explore the condition pages connected to this study.